AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35377934
Drug: Mock PDL
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock PDL injection and conventional palatal infiltration
Trial: 33982892
Drug: Genetically determined
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically determined fasting insulin concentrations
Trial: 33982892
Drug: Outlier-corrected fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outlier-corrected fasting insulin concentrations
Trial: 33982892
Drug: Polygenic scores
RxNorm normalized name: polygalic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polygenic scores for fasting insulin
Trial: 35199478
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of esaxerenone and SGLT2 inhibitor
Trial: 38874618
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor
Trial: 34221093
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (opioid analgesics) with no additional interventions
Trial: 34312190
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (sublingual or oral) at 50, 100 or 200 mg daily over 3 days
Trial: 34312190
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (oral vs sublingual)
Trial: 34426064
Drug: Monthly group‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group‐based diabetes self‐management education (DSME) and monthly vouchers ($28‐$140/month) redeemable for fruits and vegetables at local markets
Trial: 32987647
Drug: Colostrum (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum (2 × 500 mg) harvested at 2 hours after delivery
Trial: 32987647
Drug: Colostrum (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum (2 × 500 mg) harvested at 24 hours after delivery
Trial: 32987647
Drug: Colostrum (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum (2 × 500 mg) harvested at 72 hours after delivery
Trial: 34287475
Drug: Dengzhan Shengmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengzhan Shengmai capsule 0.36 g three times a day
Trial: 34287475
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil hydrochloride 5 mg once a day
Trial: 34596269
Drug: Low-dose intramuscular
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intramuscular testosterone treatment (1 mg/kg/month)
Trial: 34596269
Drug: Per oral
RxNorm normalized name: Amino Acids/Copper Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per oral letrozole treatment (2.5 mg/day)
Trial: 33064410
Drug: Hormones with
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormones with left eye pupil constriction difference
Trial: 33015912
Drug: 1-day low-residue
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-day low-residue diet (LRD) with standard laxative treatment
Trial: 33015912
Drug: 3-day low-residue
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day low-residue diet (LRD) with standard laxative treatment
Trial: 34655400
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium L‐threonate (MLT) for 12 weeks
Trial: 34655400
Drug: High‐dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose intravenous (IV) magnesium sulfate (MgSO4) for 3 days followed by open‐label MLT for 24 weeks
Trial: 33106853
Drug: Observational analysis;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational analysis; 1 µg/mL increase in plasma adiponectin
Trial: 33106853
Drug: One-sample Mendelian
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-sample Mendelian randomization; 1 µg/mL genetically determined increase in plasma adiponectin
Trial: 32641096
Drug: Vaginal patch
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal patch plastron
Trial: 34468881
Drug: Initial invasive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial invasive revascularization strategy with optimal medical therapy
Trial: 38212104
Drug: CC+SI
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC+SI
Trial: 32359899
Drug: ticagrelor +
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor + aspirin
Trial: 35229778
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral‐B Pro Health Gum care®)
Trial: 35229778
Drug: Powered toothbrush
RxNorm normalized name: Pro Clean Spinbrush Powered Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powered toothbrush (Oral‐B Cross action Power Dual®)
Trial: 35778941
Drug: Cognitive-behavioral-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral-based physical therapy (CBPT) intervention, 6 sessions, telephone-based
Trial: 35906549
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 30 Gy/5fx HSRT and 20 Gy/10fx IMRT with concurrent temozolomide and adjuvant chemotherapy
Trial: 36078655
Drug: Mostly Linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mostly Linear (ML; 80% linear, 20% nonlinear)
Trial: 32906135
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment arm
Trial: 32906135
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment arm
Trial: 32594854
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (BR; 985 mg/d)
Trial: 32594854
Drug: Nitrate-depleted beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-depleted beetroot juice (PLA; 0.37 mg/d)
Trial: 35599701
Drug: Low-dose anticoagulation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anticoagulation in acutely ill participants/intermediate-dose anticoagulation in critically ill participants
Trial: 616518461
Drug: Bromocriptine 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5mg once daily
Trial: 35305746
Drug: PACT-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACT-G
Trial: 32750250
Drug: Liraglutide at
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide at a dose of 1.8 mg/d
Trial: 36227352
Drug: THC-dominant cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC-dominant cannabis (13.75 mg THC)
Trial: 36227352
Drug: THC/CBD-equivalent cannabis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD-equivalent cannabis (13.75 mg THC/13.75 mg CBD)
Trial: 36227352
Drug: CBD-dominant cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD-dominant cannabis (13.75 mg CBD)
Trial: 33788464
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment at Dahe (KI 12), Zhongzhu (KI 15), Hegu (LI 4), Xuehai (SP 10) for 30 min, once a day, for 2 courses with 1-day interval.
Trial: 33788464
Drug: Oral Xinshenghua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Xinshenghua tablet, 4 tablets each time, 3 times a day for 7 days.
Trial: 34318633
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 0.5 g dissolved in 20 ml normal saline injected into femoral bone marrow cavity for local treatment
Trial: 34318633
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 20 minutes before operation, 15 mg/kg diluted in 250 ml sodium chloride injection, intravenous drip
Trial: 32345916
Drug: Liposomal CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal CBD (20 mg/day)
Trial: 32345916
Drug: Nonliposomal CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonliposomal CBD (50 mg/day)
Trial: 35236397
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioural Therapy (Reframe IT) for high-risk students
Trial: 34131763
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy along with conventional management
Trial: 36050653
Drug: Temozolomide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (50 mg/m2 for 3 months)
Trial: 616116613
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment guided by VA stabilization
Trial: 616116613
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment guided by disease activity
Trial: 35083559
Drug: Novel balloon
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel balloon catheter dilation therapy
Trial: 35083559
Drug: 14-Fr ordinary
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-Fr ordinary urinary catheter dilation therapy
Trial: 33787926
Drug: Standard Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Behavioral Therapy (SBT)
Trial: 32349117
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d oral tropisetron
Trial: 32349117
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d oral tropisetron
Trial: 32349117
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d oral tropisetron
Trial: 33162246
Drug: Urethral bulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral bulking agent injection
Trial: 33151955
Drug: Intervention (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (low energy diet, exercise training, optimized treatment of hypertension, dyslipidemia, and diabetes)
Trial: 35331641
Drug: Veliparib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (120 mg daily for 7 days/cycle) with carboplatin and paclitaxel
Trial: 35331641
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (investigator's choice of platinum doublet chemotherapy, up to 6, 21-day cycles)
Trial: 33288685
Drug: Low-dose endotoxin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose endotoxin (LPS) injection
Trial: 33288685
Drug: LPS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS treatment in mice
Trial: 32843515
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral pudendal nerve block (PNB) with 0.25% ropivacaine 10 mL
Trial: 32843515
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 10 mL saline
Trial: 34295981
Drug: Placebo (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (140 mg)
Trial: 32556768
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg/day intravenously for 3 days followed by 40 mg/day orally for 4 weeks)
Trial: 34297677
Drug: Active Breaks
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Breaks Program (20 periods of weekly ABs, 5-10 minutes, 3-5 times a day for 17 weeks)
Trial: 36102762
Drug: Senior Chef
RxNorm normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senior Chef programme (SC group) - 8-week nutrition education and cooking class (3 hours weekly)
Trial: 36102762
Drug: Steady As
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady As You Go programme (SAYGO group) - 10-week strength and balance exercise programme (1 hour weekly)
Trial: 33577011
Drug: Anti‐β2 glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐β2 glycoprotein I antibody IgA/G/M
Trial: 32237143
Drug: Group game
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group game intervention including routine preoperative preparation and group game
Trial: 36436532
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy with aerobic exercise (10 min aerobic exercise after nine 90‐min weekly sessions of exposure therapy)
Trial: 36436532
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy with passive stretching (10 min passive stretching after nine 90‐min weekly sessions of exposure therapy)
Trial: 32184123
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) 3 g intravenous infusion
Trial: 32184123
Drug: Placebo (PL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL, 0.9% NaCl) intravenous infusion
Trial: 35331007
Drug: Intensive BG
RxNorm normalized name: BG-777
DrugBank: BG-777 (DB05839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive BG control (target BG 80-130 mg/dL) for 72 hours
Trial: 35331007
Drug: Standard BG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BG control (target BG 80-179 mg/dL) for 72 hours
Trial: 34273114
Drug: Miscanthus planted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miscanthus planted in tilled soil amended with organic P (Class B biosolids applied at 45 Mg ha‐1)
Trial: 33982083
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to antiretroviral therapy (ART)
Trial: 34782191
Drug: Adjunctive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive oral dexamethasone
Trial: 33060531
Drug: Routine hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hydration (1 ml/kg/h, 0.9% sodium chloride) for 3-12 hours before and 24 hours after contrast exposure
Trial: 35110644
Drug: NeoRehab program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeoRehab program (parent-provided interventions including vocal soothing, scent exchange, comforting touch, skin-to-skin care, massage, and physical therapy)
Trial: 35980648
Drug: Individualised management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised management combined with drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Trial: 35980648
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Trial: 35980648
Drug: Individualised management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised management combined with drug treatment
Trial: 35843106
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of fructooligosaccharide (FOS)
Trial: 35843106
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of partially hydrolyzed guar gum (PHGG)
Trial: 35843106
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of digestible maltodextrin (placebo)
Trial: 33470727
Drug: Daily financial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily financial incentives linked to real-time adherence monitoring
Trial: 32333898
Drug: Satralizumab 120
RxNorm normalized name: satralizumab 120 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satralizumab 120 mg
Trial: 33464762
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (1st line treatment)
Trial: 33464762
Drug: Rituximab (2nd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (2nd line treatment)
Trial: 32746841
Drug: Occupation-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupation-based intervention supported with problem-solving therapy
Trial: 35449020
Drug: Tolvaptan (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (initial dose 7.5 mg)
Trial: 35449020
Drug: Fluid restriction
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid restriction (initial limit 1000 ml per 24 h)
Trial: 32314298
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal agent + CO2 laser ablation once a month for the first 3 months
Trial: 32314298
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal agent
Trial: 32314298
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal agent + CO2 laser ablation
Trial: 33966560
Drug: BARKH-based algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BARKH-based algorithm for identification and treatment of hypertensive emergencies
Trial: 34669179
Drug: Sonidegib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 800 mg once daily
Trial: 34582281
Drug: Treatment seeking
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment seeking participants
Trial: 34582281
Drug: Non-treatment seeking
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment seeking participants
Trial: 32444309
Drug: SLOIT (slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLOIT (slow low-dose oral immunotherapy)
Trial: 33798303
Drug: Baduanjin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baduanjin and auricular point sticking therapy
Trial: 33798303
Drug: Estazolam 1
RxNorm normalized name: estazolam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 1 mg, once daily for 12 days
Trial: 37354048
Drug: Ritonavir 100
RxNorm normalized name: ritonavir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 100 mg
Trial: 34658360
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy with alteplase in addition to routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Trial: 34658360
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Trial: 34658360
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy with alteplase in addition to routine therapy
Trial: 34096012
Drug: Reduced ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced ticagrelor maintenance dose with or without acetylsalicylic acid (ASA) withdrawal
Trial: 34096012
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose ticagrelor with dual antiplatelet treatment (DAPT)
Trial: 32755273
Drug: Cannabidiol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (600 mg oral dose)
Trial: 32093757
Drug: Sensory intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory intervention (SI) to improve quality of life for PwD with concurrent hearing and/or vision impairment.
Trial: 35061005
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine group (10 ml liposomal bupivacaine + 10 ml 0.5% bupivacaine)
Trial: 35061005
Drug: Bupivacaine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine group (20 ml 0.5% bupivacaine)